Compare Abeona Therapeutics Inc (ABEO) vs TJX Companies Inc (TJX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs TJX Companies Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while TJX Companies Inc trades at $153.31 (market cap $170.25B). The key difference: TJX Companies Inc is far larger — about 456× Abeona Therapeutics Inc's market cap, and TJX Companies Inc pays a 1.25% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TJX | |
|---|---|---|
Market Cap | $373.32M | $170.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $168.41 |
52-Week Low | $4.17 | $121.35 |
Enterprise Value | $228.22M | $178.85B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TJX trades at $154.11, up slightly by 0.02% today, with a bearish technical signal from moving averages but strong fundamental performance. The company reported consistent earnings beats, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate, and maintains robust profitability with a 61.25% ROE. Revenue growth is steady, reaching $56.36B in 2025, supported by expansion in home goods and international markets.
Outlook remains positive with an 88% analyst buy rating and a $181.80 consensus price target, implying 18% upside. Risks include high valuation multiples like a 29.44 P/E and economic sensitivity, but strong cash flow and dividend payments provide stability. Investors should monitor Q2 2026 earnings for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
